Clinical Trial Update: Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602 [Phase 2, Phase 3]

View source ↗

Summary

This document summarizes the completion of an extension study for infantile-onset Pompe disease patients previously enrolled in protocol AGLU01602.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pompe Disease

Drugs mentioned

• Myozyme (alglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Glycogen Storage Disease Type II | Phase 2, Phase 3 | Status: COMPLETED